The battle against metastatic colorectal cancer is a challenging one, especially when it comes to the microsatellite-stable (MSS) subtype. But a new drug, Zanzalintinib, is making waves in the oncology world, offering hope where options have been scarce.
The Challenge of MSS Colorectal Cancer:
Nearly 95% of colorectal cancers are MSS, and these tumors have proven to be a formidable opponent. They are resistant to immunotherapy and largely unaffected by standard cytotoxic and biologic therapies, leaving clinicians with limited treatment options. The current go-to treatments, regorafenib and trifluridine/tipiracil, provide only modest benefits while bringing substantial toxicity. (Grothey et al., Lancet, 2013)
Enter Zanzalintinib:
Exelixis has developed Zanzalintinib, a next-generation multi-kinase inhibitor, to tackle this challenge. It's designed to overcome the angiogenic and microenvironment-driven resistance mechanisms that make MSS tumors so difficult to treat. And this is where it gets interesting...
Mechanism of Action:
Zanzalintinib, formerly known as XL092, is an oral drug that inhibits multiple tyrosine kinases, including VEGFR2, MET, AXL, and the TAM kinase family. These pathways are key players in angiogenesis, tumor invasiveness, metastasis, and immune suppression. By targeting VEGFR2 and MET simultaneously, Zanzalintinib counters the escape mechanisms that often render anti-angiogenic agents ineffective. Additionally, inhibiting AXL reduces epithelial-mesenchymal transition (EMT), a process that promotes metastasis and therapy resistance. Early studies suggest that Zanzalintinib's improved pharmacokinetics may offer better exposure and tolerability compared to its predecessor, cabozantinib. (Gao et al., Clin Cancer Res, 2021)
Why MSS Colorectal Cancer Responds:
MSS colorectal cancer is known for its aggressive nature, low mutation burden, high angiogenesis, and strong immune exclusion. It also exhibits robust EMT and metastasis signatures, along with upregulated MET/AXL signaling. Zanzalintinib directly targets these pathways, reducing angiogenesis and reversing immune evasion driven by MET and AXL.
The Impact:
This multi-pronged approach leads to decreased tumor hypoxia, improved T-cell infiltration, reduced metastatic behaviors, and enhanced immune priming. Essentially, Zanzalintinib transforms these immunologically cold tumors into more responsive ones.
The STELLAR-303 Trial:
This phase III trial tested Zanzalintinib in previously treated MSS metastatic colorectal cancer patients. The study included heavily pretreated patients with limited options, who had progressed on multiple standard therapies. Patients were randomly assigned Zanzalintinib or regorafenib, the established VEGF-targeting agent. The results were impressive: Zanzalintinib significantly improved overall survival and progression-free survival compared to regorafenib, a milestone in MSS colorectal cancer treatment in almost a decade. This benefit was seen across various subgroups, including patients with liver metastases, who typically don't respond well to immunotherapy. (STELLAR-303 Investigators, ASCO GI, 2025)
Safety and Tolerability:
Zanzalintinib's safety profile is consistent with other multi-target anti-angiogenic therapies, with hypertension, fatigue, diarrhea, and hand-foot syndrome as common side effects. However, it appears to be better tolerated than regorafenib, which has historically caused dose-limiting hand-foot syndrome and gastrointestinal issues. Zanzalintinib's optimized kinase selectivity and shorter half-life contribute to its improved tolerability, allowing for more consistent exposure and easier dose adjustments. Fewer severe adverse events and dose reductions were reported with Zanzalintinib, suggesting better treatment adherence and longer therapy duration, crucial factors in later-line metastatic settings.
Clinical Significance:
Zanzalintinib is a game-changer for MSS metastatic colorectal cancer. It directly targets the pro-angiogenic and mesenchymal signaling pathways that drive disease progression in these tumors, offering a biologically sound approach when traditional cytotoxic therapy falls short. Given the widespread resistance to immunotherapy and VEGF blockade in MSS tumors, Zanzalintinib's multi-pathway inhibition is a significant therapeutic advancement. The improved overall survival observed in the STELLAR-303 trial positions Zanzalintinib as a potential new standard of care for patients who have progressed on first- and second-line therapies.
Looking Ahead:
Preclinical research suggests that dual VEGFR2/MET blockade, as achieved by Zanzalintinib, may boost antitumor immunity by enhancing dendritic cell activation and reducing immunosuppressive signals in the tumor microenvironment. (Feng et al., Cancer Res, 2022) This has sparked interest in combining Zanzalintinib with checkpoint inhibitors, especially in MSS colorectal cancer, where immune resistance is a major hurdle. Trials are also underway to explore Zanzalintinib's potential in other tumors, such as renal cell carcinoma and hepatocellular carcinoma, where MET and AXL signaling are involved. As more data emerges, Zanzalintinib could become a cornerstone of modern targeted therapy, offering hope to patients with various solid tumors.
Controversy and Discussion:
While Zanzalintinib shows great promise, it's important to consider potential challenges. One might argue that the focus on MSS colorectal cancer, a relatively rare subtype, limits the drug's overall impact. Additionally, the long-term effects and optimal patient selection criteria for Zanzalintinib remain to be fully understood. How do you think Zanzalintinib will shape the future of metastatic colorectal cancer treatment? Are there specific patient populations that could benefit the most? Share your thoughts and join the discussion!
